SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017Adaptive Immunity: Therapeutic vaccination, checkpoint inhibition and potential others- Andre Boonstra, PhDView Slideset
AGAdam GehringPhDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017Innate Immunity : TLR, RIG-I, STING and potential others- Adam Gehring, PhDView Slideset
HJHarry JanssenMD, PhDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017Is immunomodulation really needed to cure HBV?- Harry Janssen, MD, PhDView Slideset
MMMala MainiMD, PhDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017How does HBV interact with the immune system- Mala Maini, MD, PhDView Slideset
FZFabien ZoulimMD, PhDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017Hepatitis B Cure: From Discovery to Regulatory Endpoints in HBV clinical research: A summary of the AASLD/EASL statement- Fabien Zoulim, MD, PhDView Slideset
PLPietro LamperticoMD, PhDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017TAF – The latest update, which questions remain to be answered?- Pietro Lampertico, MD, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017Influence of Bacterial Growth Rate on Dose Optimization of Linezolid for Treatment of Tuberculosis- Kristina BigelowView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017Prediction of increase in time-to-positivity after higher doses of rifampicin based on pharmacokinetic-pharmacodynamic modelling- Robin SvenssonView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017Quantitative Analysis of MGIT Time to Positivity Using a Two-Part Longitudinal Model in Patients with Pulmonary Tuberculosis: A Meta-Analysis of 11 Clinical Studies Including 30 Unique Regimens- Nastya Kassir, PharmD, PhD, FCPView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017Pharmacokinetics of rifampicin in African children - Evaluation of the new WHO dosing guidelines- Paolo DentiView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017A Cardiac Risk Algorithm to Predict the Probability of Drug-Induced Torsades de Pointes with Novel Anti-TB Agents- Alexander Berg, PharmD, PhD, FCPView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017Ototoxicity is associated with exposure to kanamycin and capreomycin in the treatment of multidrug-resistant tuberculosis- Mohammed AslshaerView Slideset
